BMS-981164 / BMS - LARVOL DELTA

Engineering and Development of a Novel Bispecific Antibody Targeting IL13 and IL31 (AAD 2026) - " The bsAb binds IL13 with sub-nanomolar affinity, effectively inhibiting IL13-induced downstream signaling and TF-1 cell proliferation, with potency comparable to the benchmark Lebrikizumab analogue. Meanwhile, the bsAb demonstrates sub-nanomolar affinity for IL31 and similar blocking activity to BMS-981164 in both IL31R reporter and CCL2 release assays... The bsAb simultaneously targets IL13 and IL31, effectively suppressing key inflammatory signals and pruritus symptoms, while also delivering a synergistic effect. It holds great potential to improve therapeutic efficacy for patients with atopic dermatitis and other skin inflammation."

Bispecific • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Pruritus • CCL2 • IL13 • IL1R1 • IL6

Engineering and Development of a Novel Bispecific Antibody Targeting IL13 and IL31 (AAAAI 2026) - "Results The bsAb demonstrates sub-nanomolar affinity for IL13, effectively inhibiting IL13-induced downstream signaling and TF-1 cell proliferation, with potency comparable to the benchmark Lebrikizumab analogue. Meanwhile, the bsAb shows sub-nanomolar affinity for IL31 and similar blocking activity to BMS-981164 in both IL31R reporter and CCL2 release assays...Conclusions The bsAb simultaneously blocks IL13 and IL31, effectively inhibiting key inflammatory signals and pruritus symptoms, while also exhibiting a synergistic effect. It holds great potential to improve therapeutic efficacy for patients with atopic dermatitis and other skin inflammation."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • CCL2 • IL13 • IL1R1 • IL6

A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis. (PubMed, JID Innov) - "In reporter cell lines, NM26-2198 concomitantly inhibited IL-4/IL-13 and IL-31 signaling with a potency comparable with that of the combination of an anti-IL-4Rα antibody (dupilumab) and an anti-IL-31 antibody (BMS-981164). In a repeat-dose, good laboratory practice toxicology study in cynomolgus monkeys, no adverse effects of NM26-2198 were observed at a weekly dose of 125 mg/kg. Together, these results justify the clinical investigation of NM26-2198 as a treatment for moderate-to-severe AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • FCER2 • FCGR2A • FCGR2B • IL13 • IL4